Missense mutations of the BRAF gene in human lung adenocarcinoma

Cancer Research

Volumn 62, Issue 23, 2002, Pages 7001-7003

  Naoki, Katsuhiko ^a   Chen, Tzu Hsiu ^a   Richards, William G ^b   Sugarbaker, David J ^b   Meyerson, Matthew ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE BRAF; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG TARGETING; EXON; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATION RATE; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF;

EID: 0036895599     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA Cancer J. Clin., 52: 23-47, 2002.
2. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037, 2001.
3. Travis, W. D., Travis, L. B., and Devesa, S. S. Lung cancer. Cancer (Phila.), 75: 191-202,1995.
4. Rodenhuis, S., van de Wetering, M. L., Mooi, W. J., Evers, S. G., van Zandwijk, N., and Bos, J. L. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N. Engl. J. Med., 317: 929-935, 1987.
5. Kwiatkowski, D. J., Harpole, D. H., Jr., Godleski, J., Hemdon, J. E. N., Shieh, D. B., Richards, W., Blanco, R., Xu, H. J., Strauss, G. M., and Sugarbaker, D. J. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications. J. Clin. Oncol., 16: 2468-2477, 1998.
6. Peyssonnaux, C., and Eychene, A. The Raf/MEK/ERK pathway: New concepts of activation. Biol. Cell, 93: 53-62, 2001.
7. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature (Lond.), 417: 949-954, 2002.
8. Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., Loda, M., Weber, G., Mark, E. J., Lander, E. S., Wong, W., Johnson, B. E., Golub, T. R., Sugarbaker, D. J., and Meyerson, M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA, 98: 13790-13795, 2001.
9. Sanger, F., and Coulson, A. R. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J. Mol. Biol., 94: 441-448. 1975.
10. Li. C., and Wong, W. H. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc. Natl. Acad. Sci. USA, 98: 31-36, 2001.
11. 1 progression in NIH 3T3 cells. Mol. Cell. Biol., 15: 3654-3663, 1995.
12. Lavoie, J. N., L'Allemain, G., Brunet, A., Muller, R., and Pouyssegur, J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem., 271: 20608-20616, 1996.
13. Kerkhoff, E., and Rapp, U. R. Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol. Cell. Biol., 17: 2576-2586, 1997.
14. Woods, D., Parry, D., Cherwinski, H., Bosch, E., Lees, E., and McMahon, M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol., 17: 5598-5611, 1997.
15. 1 cell cycle progression. J. Biol. Chem., 274: 22033-22040, 1999.
16. Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (Lond.), 418: 934, 2002.
17. Lyons, J. F., Wilhelm, S., Hibner, B., and Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer, 8: 219-225, 2001.
18. Cripps, M. C., Figueredo, A. T., Oza, A. M., Taylor, M. J., Fields, A. L., Holmlund, J. T., McIntosh, L. W., Geary, R. S., and Eisenhauer, E. A. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Clin. Cancer Res., 8: 2188-2192, 2002.
19. Coudert, B., Anthoney, A., Fiedler, W., Droz, J. P., Dieras, V., Borner, M., Smyth, J. F., Morant, R., de Vries, M. J., Roelvink, M., and Fumoleau. P. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur. J. Cancer, 37: 2194-2198, 2001.